Stock Alert: Why Does Capricor Therapeutics’ Share Jump 252% Today?

Shares of the California-based biotech Capricor Therapeutics skyrocket by more than 252% on positive COVID-19 treatment data. A small study showed a survival rate of 100% in 6 COVID-19 patients treated with the company’s lead drug candidate CAP-1002.

Capricor’s lead drug candidate CAP-1002 is a cardiac-derived cell therapy which is under investigation as a potential treatment for patients with Duchenne muscular dystrophy. According to the biotech, 6 coronavirus-infected patients with respiratory distress syndrome hospitalized at Cedars-Sinai Medical Center fully recovered after a one-month treatment with CAP-1002. The company aims at getting more clarity on the efficacy of CAP-1002 by expanding treatment to 20 additional COVID-19 patients.

Although Capricor’s stock is trading at $8.50 (+252.70%) on the NASDAQ today, Biotech Investments does not recommend an investment at this point. The number of patients in the study is very low and a placebo group is missing, potentially affecting the meaningfulness of the trial results.

The full press release of Capricor Therapeutics can be read here.



April 29, 2020 Biotech, Capricor Therapeutics, News

Leave a Reply

Your email address will not be published. Required fields are marked *